These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22515)

  • 21. A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia.
    Pinto R; Bannerjee A; Ghosh N
    Acta Psychiatr Scand; 1979 Oct; 60(4):313-22. PubMed ID: 390972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High vs standard dosage fluphenazine HCL in acute schizophrenia.
    Donlon PT; Meadow A; Tupin JP; Wahba M
    J Clin Psychiatry; 1978 Nov; 39(11):800-4. PubMed ID: 363702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluphenazine plasma levels and clinical response.
    Marder SR; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J; Midha KK
    Psychopharmacol Bull; 1990; 26(2):256-9. PubMed ID: 2236467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia.
    Johnson DA; Malik NA
    Acta Psychiatr Scand; 1975 May; 51(4):257-67. PubMed ID: 1096536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Standard and long-acting depot neuroleptics in chronic schizophrenics: an 18-month open multicentric study.
    Simon P; Fermanian J; Ginestet D; Goujet MA; Péron-Magnan P
    Arch Gen Psychiatry; 1978 Jul; 35(7):893-7. PubMed ID: 28102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 29. A one-year double-blind comparison of long-acting oral (penfluridol) versus long-acting injectable (fluphenazine decanoate) antipsychotic drugs in multiple-episode schizophrenics.
    Quitkin F; Rifkin A; Klein DF
    Psychopharmacol Bull; 1977 Jul; 13(3):27-9. PubMed ID: 329327
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical experience with pipothiazine palmitate (19552 R.P.) in hospitalized and open ward patients with functional psychoses.
    Salvesen C; Vaksdal K
    PDM; 1974; 5-6(9-12;1-8):10-4. PubMed ID: 4156935
    [No Abstract]   [Full Text] [Related]  

  • 31. Potential value of penfluridol and pipothiazine palmitate.
    Gallant DM
    Psychopharmacol Bull; 1975 Jan; 11(1):11-2. PubMed ID: 235769
    [No Abstract]   [Full Text] [Related]  

  • 32. Early hospital experience with fluphenazine decanoate.
    Small JG; Kellams J
    Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W; Boisvert D; Bradwejn J
    Psychopharmacol Bull; 1984; 20(1):108-9. PubMed ID: 6371871
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
    Altamura AC; Mauri MC; Girardi T; Panetta B
    Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three years' maintenance neuroleptic treatment in schizophrenia--before and beyond.
    Dencker SJ; Frankenberg K; Lepp M; Lindberg D; Malm U
    Acta Psychiatr Scand; 1978 Feb; 57(2):103-14. PubMed ID: 24981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A preliminary evaluation of pipothiazine palmitate in schizophrenia.
    Imlah NW; Murphy KP
    Curr Med Res Opin; 1975; 3(3):169-74. PubMed ID: 238791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
    Eklund K; Forsman A
    Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A controlled one-year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Evaluation of results at 6 and 12 months' trial.
    Dencker SJ; Frankenberg K; Malm U; Zell B
    Acta Psychiatr Scand Suppl; 1973; 241():101-18. PubMed ID: 4147508
    [No Abstract]   [Full Text] [Related]  

  • 40. A comparative trail of fluphenazine decanoate and flupenthixol decanoate.
    Haslam MT; Bromham BM; Schiff AA
    Acta Psychiatr Scand; 1975 Feb; 51(2):92-100. PubMed ID: 1091124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.